1610875-62-1

Basic information

• Product Name: 4-(2-(2-bromo-5-nitrophenoxy)ethyl)morpholine
• Synonyms: 4-(2-(2-bromo-5-nitrophenoxy)ethyl)morpholine
• CAS NO: 1610875-62-1
• Molecular Weight: 331.166
• Mol File: 1610875-62-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(2-(2-bromo-5-nitrophenoxy)ethyl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-(2-bromo-5-nitrophenoxy)ethyl)morpholine(1610875-62-1)
• EPA Substance Registry System: 4-(2-(2-bromo-5-nitrophenoxy)ethyl)morpholine(1610875-62-1)

Safety Data

• Hazardous Substances Data: 1610875-62-1(Hazardous Substances Data)

Upstream product

• 3240-94-6 N-(2-chlorethyl)morpholine 
• 52427-05-1 2-bromo-5-nitrophenol 

Downstream Products

• 1610875-05-2 2-(2-chlorophenyl)-N-(3-(2-morpholinoethoxy)-4-(1H-pyrazol-4-yl)phenyl)acetamide 2,2,2-trifluoroacetate 
• 1610875-63-2 4-bromo-3-(2-morpholinoethoxy)aniline 
• 1610875-64-3 N-(4-bromo-3-(2-morpholinoethoxy)phenyl)-2-(2-chlorophenyl)acetamide 
• 1610875-65-4 tert-butyl 4-(4-(2-(2-chlorophenyl)acetamido)-2-(2-morpholinoethoxy)phenyl)-1H-pyrazole-1-carboxylate 

Relevant articles and documents

SUBSTITUTED HETEROCYCLIC DERIVATIVES

The present invention relates to compounds of general formula (I-1) or (I-2) wherein R1 is hydrogen, lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; R1' is hydrogen, lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; with the proviso that both R1 and R1' may be simultaneously hydrogen, but only one of R1 and R1' is lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; Het is a 5-or 6 membered heteroaryl group, wherein the heteroatom is selected from N, O or S; X is -CRR'-, -CRR'-NR'-, -C(O)-, -CH2-S-, -CH2-S(O)2-, CH2-O- or -CH2-CRR'-; R/R' are independently from each other hydrogen, lower alkyl, hydroxy or phenyl, or R and R' may form together with the carbon atom to which they are attached a cyclopropyl ring; R2 is lower alkyl, -C(O)O-lower alkyl, C3-6-cycloalkyl optionally substituted by lower alkyl or =O, bridged cyclohexyl or C3-6-cycloalkenyl, or is a 5-membered heteroaryl group, wherein the heteroatom is selected from N, O or S and which is optionally substituted by one or more lower alkyl, or is pyridinyl, optionally substituted by halogen or lower alkoxy; or is phenyl, optionally substituted by one or more R2', selected from halogen, cyano, S(O)2-lower alkyl, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen or amino, or is benzo[1,3]dioxolyl, naphthyl, indolyl, benzo-isoxazolyl, 2,3-dihydro-1H-indenyl, optionally substituted by lower alkoxy or by an oxo group, or is 3,4-dihydro-2H- [1,4]oxazinyl, optionally substituted by an oxo group, or is a five or six membered heterocycloalkyl group; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.